MCID: OPT003
MIFTS: 50

Opiate Dependence malady

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

Aliases & Descriptions for Opiate Dependence:

Name: Opiate Dependence 12 14
Opioid-Related Disorders 42 69
Opioid Type Dependence 12
Opioid Dependence 52
Opiate Addiction 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD10 33 F11.2
ICD9CM 35 304.0 304.00
MeSH 42 D009293
UMLS 69 C0524662

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid-related disorders, is related to personality disorder and opioid dependence 1. An important gene associated with Opiate Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and endothelial, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Related Disease Score Top Affiliating Genes
1 personality disorder 29.2 DRD2 DRD3 FOS OPRM1 PDYN POMC
2 opioid dependence 1 12.1
3 heroin dependence 10.9
4 morphine dependence 10.9
5 sphenoorbital meningioma 10.2 DRD2 DRD3 TH
6 vaginal adenoma 10.2 IGF1 POMC
7 cytomegalic congenital adrenal hypoplasia 10.2 DRD2 DRD3 TH
8 acute contagious conjunctivitis 10.1 DRD2 OPRM1 PDYN
9 urea cycle disorder 10.1 DRD2 IGF1 NGF
10 c8 deficiency, type ii 10.1 CREB1 DRD2 DRD3 OPRM1
11 bile acid synthesis defect, congenital, 4 10.1 DRD2 IGF1 POMC
12 hepatic vascular disease 10.1 POMC VEGFA
13 cold-induced sweating syndrome 2 10.1 DRD2 IGF1 POMC
14 cavernous hemangioma 10.1 DRD2 DRD3 TH
15 rheumatic encephalitis 10.1 IGF1 POMC VEGFA
16 adamantinous craniopharyngioma 10.1 DRD2 IGF1 POMC
17 benign epilepsy with centrotemporal spikes 10.1 CREB1 DRD2 POMC TH
18 psychotic disorder 10.1
19 brain glioblastoma multiforme 10.1 CREB1 DRD2 DRD3 TH
20 peripheral vertigo 10.0 OPRD1 OPRK1 OPRM1
21 inflammatory bowel disease 4 10.0 FOS TH
22 dysautonomia 10.0 CREB1 FOS IGF1
23 siberian tick typhus 10.0 CREB1 FOS PDYN
24 autism spectrum disorder 10.0 OPRM1 PDYN POMC
25 simultanagnosia 9.9 OPRK1 OPRM1 PDYN POMC
26 alcohol dependence 9.9
27 retinoblastoma 9.9 DRD2 DRD3 PDYN
28 autoimmune disease of endocrine system 9.9 FOS OPRM1 PDYN POMC
29 ellis-van creveld syndrome 9.9 DRD2 DRD3 FOS TH
30 neuronitis 9.9
31 hepatitis 9.9
32 pheochromocytoma 9.8 CREB1 FOS NGF POMC TH
33 cervicitis 9.8 FOS OPRD1 OPRK1 OPRM1
34 18p deletion syndrome 9.8 AUTS2 DRD2 OPRD1 OPRM1 PDYN
35 attention deficit-hyperactivity disorder 9.8
36 hepatitis c 9.8
37 schizophrenia 9.8
38 transmitted_by 9.8 DRD2 DRD3 OPRK1 OPRM1 PDYN POMC
39 hypereosinophilic syndrome 9.7 DRD2 DRD3 OPRD1 OPRK1 OPRM1 POMC
40 cervical carcinosarcoma 9.7 FOS OPRK1 OPRM1 PDYN POMC
41 sudden infant death syndrome 9.6
42 endotheliitis 9.6
43 hepatitis b 9.6
44 borderline personality disorder 9.6
45 pertussis 9.6
46 premature ejaculation 9.6
47 anxiety disorder 9.6
48 cerebritis 9.6
49 hepatitis c virus 9.6
50 hyperglycemia 9.6

Comorbidity relations with Opiate Dependence via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety Disorder
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Osteoporosis

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 AUTS2 CREB1 DRD2 DRD3 FOS NGF
2 homeostasis/metabolism MP:0005376 10.21 CREB1 DRD2 DRD3 FOS FYB IGF1
3 growth/size/body region MP:0005378 10.18 AUTS2 CREB1 DRD2 DRD3 FOS IGF1
4 endocrine/exocrine gland MP:0005379 10.13 FYB IGF1 OPRK1 OPRM1 POMC TH
5 cellular MP:0005384 10.11 CREB1 DRD2 FOS FYB IGF1 OPRM1
6 cardiovascular system MP:0005385 10.08 CREB1 DRD2 DRD3 IGF1 NGF POMC
7 integument MP:0010771 10.06 PDYN POMC TH VEGFA DRD2 FOS
8 adipose tissue MP:0005375 9.99 IGF1 OPRM1 PDYN POMC DRD2 DRD3
9 nervous system MP:0003631 9.97 TH VEGFA CREB1 DRD2 DRD3 FOS
10 neoplasm MP:0002006 9.73 DRD2 FOS IGF1 POMC TH VEGFA
11 no phenotypic analysis MP:0003012 9.61 AUTS2 DRD2 NGF OPRD1 OPRM1 PDYN
12 normal MP:0002873 9.23 CREB1 DRD2 FOS IGF1 NGF OPRM1

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 356)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
2
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
3
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
4
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
5
Ropivacaine Approved Phase 4,Phase 2,Phase 1 84057-95-4 71273 175805
6
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
7
Nalbuphine Approved Phase 4 20594-83-6 5360630 5311304
8
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
9
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 437-38-7 3345
11
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 465-65-6 5284596
12
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
13
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 50-36-2 5760 446220
14
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
15
Dextromethorphan Approved Phase 4,Phase 3,Phase 2 125-71-3 5360696 5362449
16
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 466-99-9 5284570
17
Nicotine Approved Phase 4,Phase 3,Phase 1,Phase 2 54-11-5 942 89594
18
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
19
Remifentanil Approved Phase 4 132875-61-7 60815
20
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
21
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 1,Phase 2 76631-46-4, 113775-47-6 68602 5311068 56032
22
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1 137-58-6 3676
23
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-42-6 5284603
24
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
25
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
26
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
27
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
28
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
29
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
30
Ephedrine Approved Phase 4 299-42-3 9294
31
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
32
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
33
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
34
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
35
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
36
Pseudoephedrine Approved Phase 4 90-82-4 7028
37
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 1 27203-92-5 33741
38
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
39
Magnesium Sulfate Approved, Vet_approved Phase 4 7487-88-9 24083
40
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
41
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
42
Hydrocodone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 125-29-1 5284569
43
Methylnaltrexone Approved Phase 4,Phase 2 83387-25-1, 916055-93-1 6603824
44
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
45
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
46
Copper Approved Phase 4 15158-11-9, 7440-50-8 27099
47
Desogestrel Approved Phase 4 54024-22-5 40973
48
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
49
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
50
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9

Interventional clinical trials:

(show top 50) (show all 676)
id Name Status NCT ID Phase
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
4 Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia Unknown status NCT01703130 Phase 4
5 Interaction Between Nalbuphine and Morphine in PCA Unknown status NCT00155233 Phase 4
6 Feasibility Study of Take-Home LAAM Medication - 3 Completed NCT00000300 Phase 4
7 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4
8 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4
9 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4
10 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4
11 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4
12 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4
13 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4
14 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
15 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
16 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4
17 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4
18 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4
19 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4
20 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4
21 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4
22 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4
23 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
24 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
25 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4
26 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
27 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4
28 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4
29 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4
30 Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy Completed NCT02327923 Phase 4
31 Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch Completed NCT01411891 Phase 4
32 Impact of Tolerability Issues on Chronic Pain Completed NCT01484301 Phase 4
33 Home Care Management of Pediatric Pain Completed NCT00251628 Phase 4
34 Adult Patients Undergoing Open Colectomy MA402S23B303 Completed NCT01507246 Phase 4
35 Does Pre and Postoperative Dextromethorphan Reduce Post-tonsillectomy Pain in Children? Completed NCT02727491 Phase 4
36 A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). Completed NCT01957046 Phase 4
37 Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries Completed NCT02508857 Phase 4
38 Ultrasound-guided Blocks for Ambulatory Knee Arthroscopy Completed NCT01837394 Phase 4
39 Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks Completed NCT01231204 Phase 4
40 Study of EXPAREL in Patients Undergoing Breast Augmentation Completed NCT01582490 Phase 4
41 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4
42 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
43 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
44 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4
45 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4
46 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4
47 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4
48 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4
49 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4
50 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

39
Testes, Brain, Endothelial, Cortex, Prefrontal Cortex

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 242)
id Title Authors Year
1
Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices. ( 26771870 )
2016
2
Influence of Psychiatric and Personality Disorders on Smoking Cessation Among Individuals in Opiate Dependence Treatment. ( 27064523 )
2016
3
Frontal Metabolite Concentration Deficits in Opiate Dependence Relate to Substance Use, Cognition, and Self-Regulation. ( 27695638 )
2016
4
TPH1 and 5-HTTLPR Genes Specifically Interact in Opiate Dependence but Not in Alcohol Dependence. ( 27045756 )
2016
5
An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. ( 26990598 )
2016
6
Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L. ( 27712710 )
2016
7
A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study). ( 26753792 )
2016
8
A thalamic input to the nucleus accumbens mediates opiate dependence. ( 26840481 )
2016
9
Role of Temperament, Personality Traits and Onset Age of Smoking in Predicting Opiate Dependence. ( 26870712 )
2015
10
Retention in Medication-Assisted Treatment for Opiate Dependence: A Systematic Review. ( 26467975 )
2015
11
Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. ( 26711857 )
2015
12
Analysis of connectivity in NeuCube spiking neural network models trained on EEG data for the understanding of functional changes in the brain: A case study on opiate dependence treatment. ( 26000776 )
2015
13
Interim Buprenorphine Treatment in Opiate Dependence: A Pilot Effectiveness Study. ( 26176490 )
2015
14
Buprenorphine for opiate dependence: clinic based therapy in Israel. ( 25841225 )
2014
15
Opiate dependence in schizophrenia: case presentation and literature review. ( 25392062 )
2014
16
Manifold implications of forgotten hyperglycemia in clinical opiate dependence. ( 22313373 )
2013
17
Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. ( 22703715 )
2013
18
Duration of opiate exposure as a determinant of arterial stiffness and vascular age in male opiate dependence: a longitudinal study. ( 24329809 )
2013
19
Exercise as an adjuvant intervention in opiate dependence. ( 23577897 )
2013
20
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. ( 23624062 )
2013
21
Elevated IGF1 in clinical opiate dependence. ( 23524620 )
2013
22
Medication-assisted treatment of opiate dependence is gaining favor. ( 23733899 )
2013
23
Effects of opiate dependence through different administration routes on pulmonary inflammation and its severity. ( 24693370 )
2013
24
Enlarged cavum septum pellucidum as a neurodevelopmental marker in adolescent-onset opiate dependence. ( 24205275 )
2013
25
Receipt of prescribed controlled substances by adolescents and young adults prior to presenting for opiate dependence treatment. ( 24826367 )
2013
26
Take home maintenance medication in opiate dependence. ( 23837085 )
2013
27
Association between DRD2, 5-HTTLPR, and ALDH2 genes and specific personality traits in alcohol- and opiate-dependent patients. ( 23685324 )
2013
28
Opiate dependence as an independent and interactive risk factor for arterial stiffness and cardiovascular ageing - a longitudinal study in females. ( 23976908 )
2013
29
Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. ( 23660707 )
2013
30
Opiate dependence induces network state shifts in the limbic system. ( 23911767 )
2013
31
Alpha-synuclein and heroin craving in opiate-dependent patients on injectable heroin maintenance. ( 21309955 )
2012
32
Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: a comparison of feasibility and validity. ( 22647899 )
2012
33
Premature ejaculation and other sexual dysfunctions in opiate dependent men receiving methadone substitution treatment. ( 21920671 )
2012
34
Differing age related trajectories of dysfunction in several organ systems in opiate dependence. ( 21339699 )
2012
35
Effect of craving induction on inhibitory control in opiate dependence. ( 21952672 )
2012
36
KPNA3 variation is associated with schizophrenia, major depression, opiate dependence and alcohol dependence. ( 22960338 )
2012
37
Relative and age-dependent stimulation of soluble and cellular immunity in opiate dependence. ( 21918466 )
2012
38
Association of nerve growth factor and vascular endothelial growth factor A with psychometric measurements of opiate dependence: results of a pilot study in patients participating in a structured diamorphine maintenance program. ( 22517242 )
2012
39
Deterioration of indices of aortic augmentation and vascular age predate major cardiac events and interact with opiate dependence. ( 19327850 )
2011
40
Serum levels of BDNF are associated with craving in opiate-dependent patients. ( 21890593 )
2011
41
Pharmacological treatments of opiate dependence. ( 21524267 )
2011
42
The effect of pain on stroop performance in patients with opiate dependence in sustained remission. ( 21769047 )
2011
43
Functional imaging of emotion reactivity in opiate-dependent borderline personality disorder. ( 22448769 )
2011
44
Lapse and relapse following inpatient treatment of opiate dependence. ( 20669601 )
2010
45
Estimation of cutoff for the Severity of Dependence Scale (SDS) for opiate dependence by ROC analysis. ( 21117001 )
2010
46
Differences between men and women in the course of opiate dependence: is there a telescoping effect? ( 19838765 )
2010
47
Association between Novelty Seeking of opiate-dependent patients and the catechol-O-methyltransferase Val(158)Met polymorphism. ( 20728009 )
2010
48
Buprenorphine in the treatment of opiate dependence. ( 20648912 )
2010
49
Relationship between anxiety disorders and opiate dependence--a systematic review of the literature: implications for diagnosis and treatment. ( 20116963 )
2010
50
Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. ( 19004598 )
2009

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
2
Show member pathways
13.43 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
3
Show member pathways
12.56 CREB1 DRD2 DRD3 FOS TH
4
Show member pathways
12.5 DRD2 FYB IGF1 NGF VEGFA
5 12.43 CREB1 IGF1 NGF VEGFA
6
Show member pathways
12.42 CREB1 FOS IGF1 NGF OPRM1 VEGFA
7
Show member pathways
12.38 CREB1 OPRM1 PDYN POMC
8
Show member pathways
12.33 CREB1 FOS OPRK1 PDYN
9 12.28 CREB1 NGF OPRM1 POMC TH
10
Show member pathways
12.24 CREB1 FOS FYB OPRM1
12 11.96 CREB1 FOS NGF
13 11.92 CREB1 NGF TH VEGFA
14
Show member pathways
11.76 DRD2 DRD3 TH
15 11.7 CREB1 FOS POMC
16 11.63 CREB1 FOS POMC
17 11.5 CREB1 FOS VEGFA
18
Show member pathways
11.42 CREB1 DRD2 FOS PDYN TH
19 11.36 IGF1 NGF TH VEGFA
20 11.35 CREB1 FOS TH
21 11.08 FOS OPRD1 OPRM1 POMC VEGFA
22 10.99 CREB1 FOS
23
Show member pathways
10.97 FOS POMC VEGFA
24 10.92 CREB1 TH
25 10.86 CREB1 FOS
26 10.8 FOS VEGFA

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.65 DRD2 OPRK1 OPRM1 PDYN TH
2 axon GO:0030424 9.62 CREB1 DRD2 OPRM1 TH
3 neuron projection GO:0043005 9.55 FOS OPRD1 OPRK1 OPRM1 TH
4 dendrite membrane GO:0032590 9.37 OPRD1 OPRM1
5 perikaryon GO:0043204 9.26 DRD2 OPRK1 OPRM1 TH
6 axon terminus GO:0043679 8.92 DRD2 OPRD1 OPRK1 PDYN

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 CREB1 DRD2 DRD3 FOS TH
2 chemical synaptic transmission GO:0007268 9.95 OPRD1 OPRK1 OPRM1 PDYN
3 response to hypoxia GO:0001666 9.93 CREB1 DRD2 TH VEGFA
4 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.83 OPRD1 OPRK1 OPRM1
5 cellular response to growth factor stimulus GO:0071363 9.82 CREB1 OPRD1 TH
6 sensory perception of pain GO:0019233 9.81 OPRD1 OPRK1 OPRM1
7 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.8 OPRD1 OPRK1 OPRM1
8 visual learning GO:0008542 9.79 CREB1 DRD2 DRD3
9 response to nicotine GO:0035094 9.79 CREB1 DRD2 TH
10 regulation of sensory perception of pain GO:0051930 9.74 OPRD1 OPRK1 OPRM1
11 negative regulation of adenylate cyclase activity GO:0007194 9.73 DRD2 DRD3 OPRM1
12 response to ethanol GO:0045471 9.72 DRD2 DRD3 OPRK1 OPRM1 TH
13 positive regulation of receptor internalization GO:0002092 9.71 DRD2 VEGFA
14 regulation of dopamine secretion GO:0014059 9.71 DRD2 DRD3
15 positive regulation of neuroblast proliferation GO:0002052 9.71 DRD2 VEGFA
16 positive regulation of osteoclast differentiation GO:0045672 9.71 CREB1 FOS
17 dopamine receptor signaling pathway GO:0007212 9.71 DRD2 DRD3
18 positive regulation of Ras protein signal transduction GO:0046579 9.7 IGF1 NGF
19 positive regulation of p38MAPK cascade GO:1900745 9.7 OPRK1 VEGFA
20 eye photoreceptor cell development GO:0042462 9.7 TH VEGFA
21 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
22 response to amphetamine GO:0001975 9.7 DRD2 DRD3 TH
23 response to corticosterone GO:0051412 9.69 FOS TH
24 response to growth factor GO:0070848 9.69 OPRM1 TH
25 positive regulation of CREB transcription factor activity GO:0032793 9.69 OPRD1 VEGFA
26 response to light stimulus GO:0009416 9.69 DRD2 FOS TH
27 behavioral response to ethanol GO:0048149 9.68 DRD2 OPRM1
28 positive regulation of long-term synaptic potentiation GO:1900273 9.68 CREB1 DRD2
29 dopamine metabolic process GO:0042417 9.68 DRD2 DRD3
30 prepulse inhibition GO:0060134 9.68 DRD2 DRD3
31 positive regulation of renal sodium excretion GO:0035815 9.67 DRD2 DRD3
32 negative regulation of protein secretion GO:0050709 9.67 DRD2 DRD3
33 G-protein coupled receptor internalization GO:0002031 9.67 DRD2 DRD3
34 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD3 OPRK1
35 response to cocaine GO:0042220 9.67 DRD2 DRD3 OPRK1 OPRM1
36 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.66 DRD2 DRD3
37 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.66 DRD3 OPRM1
38 regulation of cAMP metabolic process GO:0030814 9.65 DRD2 DRD3
39 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD3 TH
40 neuropeptide signaling pathway GO:0007218 9.65 OPRD1 OPRK1 OPRM1 PDYN POMC
41 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.63 DRD2 DRD3
42 sensory perception GO:0007600 9.63 OPRK1 OPRM1 PDYN
43 negative regulation of dopamine receptor signaling pathway GO:0060160 9.61 DRD2 DRD3
44 acid secretion GO:0046717 9.6 DRD2 DRD3
45 response to histamine GO:0034776 9.59 DRD2 DRD3
46 opioid receptor signaling pathway GO:0038003 9.58 OPRD1 OPRK1 OPRM1
47 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.55 OPRK1 OPRM1
48 regulation of locomotion involved in locomotory behavior GO:0090325 9.54 DRD2 DRD3
49 response to morphine GO:0043278 9.46 DRD2 DRD3 OPRK1 OPRM1
50 eating behavior GO:0042755 9.26 OPRD1 OPRK1 OPRM1 TH

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.71 DRD2 FYB NGF POMC
2 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.37 CREB1 FOS
3 neuropeptide binding GO:0042923 9.33 OPRD1 OPRK1 OPRM1
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD2 DRD3
5 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3
6 dopamine binding GO:0035240 9.13 DRD2 DRD3 TH
7 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....